Home Tags LEQEMBI

Tag: LEQEMBI

LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over approximately 17 Months of Treatment
Business

LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over approximately 17 Months of Treatment

Correspondent -
0
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
Business

FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

Correspondent -
0
Japan – LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference(R) (AAIC(R)) 2026
Business

Japan – LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference(R) (AAIC(R)) 2026

Correspondent -
0
Japan – “LEQEMBI(R)” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
Business

Japan – “LEQEMBI(R)” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

Leslie Atkins -
0
Japan – LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Business

Japan – LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

Leslie Atkins -
0
Japan – “LEQEMBI(R)” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
Business

Japan – “LEQEMBI(R)” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

Editor -
0
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
Business

LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

Leslie Atkins -
0
Japan – FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Business

Japan – FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Leslie Atkins -
0
Profits of LEQEMBI(R) (Preliminary Basis)
Business

Profits of LEQEMBI(R) (Preliminary Basis)

Editor -
0
Japan – Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
Business

Japan – Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Correspondent -
0
Japan – FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Business

Japan – FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Correspondent -
0
“LEQEMBI” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico
Business

“LEQEMBI” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico

Editor -
0
Japan – “LEQEMBI” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea
Business

Japan – “LEQEMBI” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea

Leslie Atkins -
0
Japan – Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
Business

Japan – Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain

-
0
Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
Business

Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

-
0
Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel
Business

Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel

Editor -
0
Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong
Business

Japan – “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong

-
0
Japan – “LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
Business

Japan – “LEQEMBI” Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea

-
0
Eisai: “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
Business

Eisai: “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China

-
0
Japan – “LEQEMBI Intravenous Infusion”Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20
Business

Japan – “LEQEMBI Intravenous Infusion”Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

-
0
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Business

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

-
0
Japan – LEQEMBI (lecanemab-Irmb) Named One of Time’s Best Inventions of 2023
Business

Japan – LEQEMBI (lecanemab-Irmb) Named One of Time’s Best Inventions of 2023

-
0
Japan – “LEQEMBI Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Business

Japan – “LEQEMBI Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

-
0